PTPRC and acute myeloid leukemia: Furthermore, ICAM-1 expression on non-malignant CD45+ immune effector cells within patient samples (Fig. 6e) significantly correlated with the efficacy of CVA21 (death of patient AML blasts) in these primary patient samples (Pearson’s r = 0.67, p = 0.009; Fig. 6f).